MapLight Therapeutics, Inc.

NASDAQ:MPLT

Biotechnology

Healthcare
$6.65 +3.11%

+$0.39 today

Market cap
$283.41M
Beta
2.65
P/E (TTM)
-2.8
EPS (TTM)
-$4.41
52W Low $9.10High $40.43

Volume 0.42M

Average 0.73M

MPLT Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

MapLight Therapeutics, Inc.NASDAQ: MPLT

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development growth accelerates

Q1 FY2026 research & development of $53.68M rose 173.6% year over year, ahead of the +136.8% change in trailing-twelve-month research & development. Sequentially, it fell 16.7% from the prior quarter. Over 3 fiscal years it compounded at +73.1% a year.

Context

  • Research & development increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +173.6% holds above the trailing-twelve-month pace of +136.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$53.68M-16.7% QoQ
Last fiscal yearDec 2025
$137.77M+103.1% YoY
LTMMar 2026
$171.97M+136.8% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+173.6%——
1 year+103.1%——
3-year CAGR+73.1%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
137.77M USD
Year-over-year change
+103.1%
3-year CAGR
+73.1%

Research & Development vs competitors

How MPLT compares with its peers on the latest reported figures

  • MPLT's LTM Mar 2026 research & development of $171.97M is the 2nd highest of the 11 companies compared; the peer median is $49.61M.
  • Its year-over-year change of +136.8% is the 2nd highest of 10, against a peer median of +19.0%.
  • Over three fiscal years its annual growth of +73.1% compares with a peer median of +21.3%.
MPLT Competitors Peer median
Research & Development for MPLT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NERVMinerva Neurosciences, Inc.LTM Jun 2026$5.27B +80515.8%-26.7%—
MPLTMapLight Therapeutics, Inc.LTM Mar 2026$171.97M +136.8%+73.1%—
DFTXDefinium Therapeutics, Inc.LTM Sep 2026$169.81M +60.3%+48.2%—
NMRANeumora Therapeutics, Inc. Common StockLTM Mar 2026$162.51M -21.6%+18.9%—
RAPPRapport Therapeutics, Inc. Common StockLTM Mar 2026$107.93M +58.7%+118.3%539.7%
ANROAlto Neuroscience, Inc.LTM Mar 2026$55.94M +19.0%+24.4%—
GHRSGH Research PLCLTM Mar 2026$43.27M +26.5%+23.7%—
AVXLAnavex Life Sciences Corp.LTM Dec 2025$31.8M -27.0%-0.3%—
OVIDOvid Therapeutics Inc.LTM Mar 2026$30.07M -8.9%+1.3%422.2%
LBRXLB Pharmaceuticals Inc Common StockLTM Mar 2026$28.47M —+131.7%—
ZVRAZevra Therapeutics, Inc.LTM Mar 2026$13.88M -59.9%-13.7%11.3%
Peer median (excluding MPLT) $49.61M+19.0%+21.3%422.2%

Competitors are the stored peer set for MPLT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue0000
Cost of Revenue574K556K701K578K
Gross Profit(574K)(556K)(701K)(578K)
Gross Margin————
Research & Development26.57M49.12M67.82M137.77M
Selling, General & Admin4.1M7.61M14.42M30.73M
Operating Expenses30.67M56.73M82.25M168.51M
Depreciation & Amortization574K556K701K578K
EBITDA(29.44M)(55.15M)(76.88M)(160.57M)
EBITDA Margin————
Operating Income(31.25M)(57.28M)(82.95M)(169.08M)
Operating Margin————
Interest Income429K1.1M4.5M5.52M
Interest Expense0000
Other Income / Expenses1.23M1.57M5.37M7.93M
Income Before Tax(30.02M)(55.71M)(77.58M)(161.15M)
Pre-Tax Margin————
Income Tax Expense0000
Net Income(30.02M)(55.71M)(77.58M)(161.15M)
Net Margin————
EPS (Basic)(0.72)(1.34)(1.87)(3.66)
EPS (Diluted)(0.72)(1.34)(1.87)(3.66)
Weighted Avg Shares41.43M41.43M41.43M44.02M
Weighted Avg Shares (Diluted)41.43M41.43M41.43M44.02M

MapLight Therapeutics, Inc.

NASDAQ:MPLT

Intrinsic Alpha fair value

Locked

Current Price

$6.65

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.